Amdocs Beats Estimates on Heels of AT&T Contract
Posted on Thursday, July 24th, 2008 | In Israel, Market CommentaryIsraeli CRM and billing systems company Amdocs (DOX) has bested analyst estimates and come through with a record quarter. The company reported record revenue of $820 million in Q2, up 15% over Q2 ‘07, solidly beating the consensus estimate of $811.06 million. Non-GAAP net profit grew 9.9% to $132.5 million, or $0.61 per share, above the analysts’ consensus of $0.60. In addition, Amdocs raised Q3 guidance as well.
Globes quotes from a Merrill Lynch report on the earnings: “We attribute the strong performance to the first complete quarter of AT&T (T) revenue recognition and better than expected execution at Sprint (S). This is the second consecutive quarter that management has raised guidance while other telecom-exposed names have been much more conservative. We note that the company has a backlog of $2.42 billion, providing management good visibility into the next few quarters.”
Merrill put a $43 target on the stock, a huge premium to the $28-29 range the stock is trading in. The company seems to really be hitting on all cylinders and with another increase in guidance, once rationale comes back into the market, Amdocs potentially could hit the Merrill target.
Aaron Katsman, IsraelNewsletter.com
Disclosure: Author’s fund has a position in DOX. He has no positions in any other stock mentioned as of 7/24/08.
Please see our Disclaimer HERE.
NEW! Introducing Israel Opportunity Investor, our monthly subscription-only newsletter. Stay ahead of the game and make smart decisions in Israel stocks. Go here to learn more.
Aaron Katsman is Managing Editor of the Israel Opportunity Investor newsletter. He is lead portfolio manager for the Israel Growth Portfolio and Managing Director of America Israel Investment Associates, LLC. For more information, go to www.israelnewsletter.com or call 1-888-327-6179, or email aaron@profile-financial.com.
Last 5 posts by Aaron Katsman
- Brrrr…. What Happened to Global Warming? - January 7th, 2009
- Israel at War With Hamas: Tel-Aviv Surges - January 4th, 2009
- ‘09 Predictions - December 31st, 2008
- Judging the ‘08 Predictions - December 24th, 2008
- Israel’s MediGuide Bought For $300 million - December 22nd, 2008
 About Aaron Katsman (http://israelnewsletter.com/)
Aaron is a managing director and the senior portfolio manager of America Israel Investment Associates, Israel Growth Portfolio (www.israelgrowth.com) where he manages a portfolio of Israeli stocks that trade in the US. He is also president of the Global Investments for Profile Investments. Aaron is a frequent contributor to StraightStocks.com, focusing on Israeli stocks. He was a founder and managed the private banking group for Citigroup in Israel for three and a half years. From 1999-2001, he was a senior analyst at a leading Israeli venture capital fund, where he gained an intimate working knowledge of the Israeli hi-tech scene. Aaron holds a B.A. in Political Science from Yeshiva University in New York. He is licensed as an investment advisor by the Israel Securities Authority and holds NASD series 7, 63, 65 in the US. |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.